Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$819.80 -13.69 (-1.64%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $854, reflecting strong market interest and potential for growth.
  • Recent insider buying activity indicates confidence in the company's future, with directors purchasing significant shares.
  • Analysts have a consensus rating of "Moderate Buy," suggesting positive sentiment and potential for price appreciation.

Cons of Eli Lilly and Company

  • Recent downgrades from some analysts, including a reduction in target prices, may indicate concerns about future growth potential.
  • The company's debt-to-equity ratio of 1.86 suggests a higher level of debt compared to equity, which could pose risks in economic downturns.
  • Market volatility and external factors, such as regulatory changes, could impact the pharmaceutical sector negatively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$775.47 billion
P/E Ratio
53.55
Consensus Rating
Moderate Buy
Consensus Price Target
$948.06 (+15.6% Upside)
Volume
1.47 million shares
Average Volume
4.09 million shares
Today's Range
$819.05
$835.32
50-Day Range
$625.15
$854.40
52-Week Range
$623.78
$937.00
Dividend Yield
0.72%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$190.30 -0.42 (-0.22%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $191, which reflects a strong market position and potential for future growth.
  • Recent upgrades from multiple analysts, including a target price increase to $212 by The Goldman Sachs Group, indicate positive market sentiment and confidence in the company's future performance.
  • Johnson & Johnson has a solid market capitalization of approximately $460 billion, showcasing its stability and ability to weather economic fluctuations.

Cons of Johnson & Johnson

  • Despite positive analyst ratings, the stock has a potential downside of about 6.90% from its current price, indicating some risk for investors.
  • Johnson & Johnson's price-to-earnings (P/E) ratio of around 20.42 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • The company has faced scrutiny and legal challenges in recent years, which could impact its reputation and stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$458.32 billion
P/E Ratio
20.35
Consensus Rating
Moderate Buy
Consensus Price Target
$192.94 (+1.4% Upside)
Volume
4.73 million shares
Average Volume
8.89 million shares
Today's Range
$189.28
$191.30
50-Day Range
$170.69
$190.97
52-Week Range
$140.68
$192.10
Dividend Yield
2.73%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$231.28 +0.78 (+0.34%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received multiple upgrades from analysts, with target prices raised significantly, indicating strong market confidence in the company's future performance.
  • The current stock price is around $231, reflecting a robust market capitalization of over $408 billion, which suggests stability and investor interest.
  • AbbVie has a diverse portfolio of products, including recent advancements in their therapeutic offerings, which can drive future revenue growth.

Cons of AbbVie

  • Insider selling has been observed, with executives reducing their holdings, which may signal a lack of confidence in the company's short-term prospects.
  • The stock has experienced fluctuations, with a recent decline of about 0.7%, indicating potential instability in the market perception of AbbVie.
  • AbbVie has a high price-to-earnings (P/E) ratio of over 110, which may suggest that the stock is overvalued compared to its earnings, posing a risk for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$408.99 billion
P/E Ratio
110.25
Consensus Rating
Moderate Buy
Consensus Price Target
$231.90 (+0.3% Upside)
Volume
3.19 million shares
Average Volume
6.48 million shares
Today's Range
$229.22
$233.81
50-Day Range
$196.37
$244.77
52-Week Range
$163.81
$244.81
Dividend Yield
2.85%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$357.76 +3.26 (+0.92%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company has demonstrated strong revenue growth, with a recent increase of approximately 12.9% compared to the same quarter last year, indicating robust business performance.
  • UnitedHealth Group has a solid return on equity of 23.32%, which reflects effective management and profitability, making it an attractive option for investors seeking strong financial performance.
  • The current stock price is around $383, which is supported by positive analyst ratings, with many firms issuing "overweight" ratings and setting high price targets, suggesting potential for price appreciation.

Cons of UnitedHealth Group

  • The company recently reported earnings per share of $4.08, which fell short of analysts' expectations of $4.45, raising concerns about its ability to meet future earnings targets.
  • Despite revenue growth, the net margin is relatively modest at 5.04%, which may limit profitability compared to competitors in the healthcare sector.
  • Some analysts have downgraded their price targets, indicating a lack of consensus on the stock's future performance, which could lead to volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$323.55 billion
P/E Ratio
15.48
Consensus Rating
Hold
Consensus Price Target
$383.09 (+7.1% Upside)
Volume
4.39 million shares
Average Volume
12.68 million shares
Today's Range
$353.32
$358.95
50-Day Range
$240.94
$369.88
52-Week Range
$234.60
$630.73
Dividend Yield
2.49%
Novartis stock logo

5. Novartis NYSE:NVS

$129.58 -0.45 (-0.35%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG has recently been rated with a "buy" by multiple analysts, indicating strong confidence in its future performance.
  • The current stock price is around $132.74, reflecting a positive trend in the market and potential for growth.
  • Recent quarterly earnings showed a significant increase in revenue, surpassing expectations, which suggests strong operational performance.

Cons of Novartis

  • Some analysts have issued "sell" ratings, indicating concerns about potential declines in stock performance.
  • The company has a relatively high debt-to-equity ratio, which may pose risks in terms of financial stability and leverage.
  • Market volatility could impact stock performance, and Novartis AG is not immune to broader economic fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$273.77 billion
P/E Ratio
18.86
Consensus Rating
Hold
Consensus Price Target
$120.33 (-7.1% Downside)
Volume
1.46 million shares
Average Volume
1.85 million shares
Today's Range
$128.83
$130.01
50-Day Range
$113.55
$132.41
52-Week Range
$96.06
$133.55
Dividend Yield
1.98%
AstraZeneca stock logo

6. AstraZeneca NASDAQ:AZN

$84.62 +0.09 (+0.10%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • AstraZeneca's stock price is currently around $85, reflecting a strong market position and investor confidence.
  • The company has received multiple "buy" ratings from analysts, indicating positive sentiment and potential for growth.
  • AstraZeneca has a robust market capitalization of approximately $264 billion, suggesting stability and the ability to invest in research and development.

Cons of AstraZeneca

  • The stock has shown some volatility, with fluctuations in price that could indicate uncertainty in the market.
  • Despite positive ratings, there is a consensus that the stock is currently at a moderate buy level, which may suggest limited upside potential in the short term.
  • AstraZeneca's quick and current ratios are below 1, which may raise concerns about its short-term liquidity and ability to cover immediate liabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$262.51 billion
P/E Ratio
31.82
Consensus Rating
Moderate Buy
Consensus Price Target
$86.00 (+1.6% Upside)
Volume
4.73 million shares
Average Volume
5.22 million shares
Today's Range
$84.05
$84.92
50-Day Range
$73.53
$85.87
52-Week Range
$61.24
$86.57
Dividend Yield
1.19%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$57.54 +0.61 (+1.07%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The company recently reported earnings per share (EPS) of $0.97, exceeding analysts' expectations, which indicates strong financial performance.
  • With a net margin of 35.60%, Novo Nordisk demonstrates effective cost management and profitability, making it an attractive investment.
  • The current stock price is around $59.63, which is significantly lower than its 1-year high of $120.56, suggesting potential for price appreciation.

Cons of Novo Nordisk A/S

  • The company recently cut its dividend, which may signal potential cash flow issues or a shift in financial strategy that could concern investors.
  • Despite strong earnings, the revenue reported was $11.69 billion, which fell short of analyst estimates, raising questions about future growth potential.
  • With a price-to-earnings ratio of 16.38, the stock may be considered overvalued compared to industry peers, which could deter some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$257.02 billion
P/E Ratio
15.81
Consensus Rating
Moderate Buy
Consensus Price Target
$77.50 (+34.7% Upside)
Volume
6.84 million shares
Average Volume
12.14 million shares
Today's Range
$57.25
$58.13
50-Day Range
$45.31
$61.86
52-Week Range
$45.05
$120.47
Dividend Yield
1.40%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$131.26 -1.32 (-0.99%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $134, reflecting a stable performance in the healthcare sector.
  • Abbott Laboratories has a strong dividend yield of 1.8%, providing a consistent income stream for investors.
  • The company has demonstrated solid financial health with a low debt-to-equity ratio of 0.25, indicating a conservative approach to leveraging.

Cons of Abbott Laboratories

  • The company's price-to-earnings (P/E) ratio of 16.58 may indicate that the stock is relatively expensive compared to its earnings, which could deter value investors.
  • Abbott Laboratories has a payout ratio of 29.57%, which, while sustainable, may limit the potential for future dividend increases.
  • Market volatility and economic uncertainties could impact Abbott Laboratories' performance, especially in the healthcare sector.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$228.55 billion
P/E Ratio
16.46
Consensus Rating
Moderate Buy
Consensus Price Target
$146.17 (+11.4% Upside)
Volume
2.46 million shares
Average Volume
6.56 million shares
Today's Range
$130.87
$132.76
50-Day Range
$129.37
$136.82
52-Week Range
$110.86
$141.23
Dividend Yield
1.78%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$85.58 -0.41 (-0.48%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $104.31, which reflects a stable valuation in the healthcare sector.
  • Merck has a strong presence in the pharmaceutical market, with a diverse portfolio that includes innovative treatments and vaccines.
  • Recent analyst ratings indicate a consensus "Hold" rating, suggesting that while there may not be immediate growth, the stock is considered stable.

Cons of Merck & Co., Inc.

  • Several analysts have recently downgraded their price targets for Merck, indicating potential concerns about future performance.
  • There has been a notable reduction in stock holdings by some institutional investors, which may signal a lack of confidence in short-term growth.
  • Merck's recent performance has been impacted by competitive pressures in the pharmaceutical industry, which could affect market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$213.73 billion
P/E Ratio
13.18
Consensus Rating
Hold
Consensus Price Target
$105.00 (+22.7% Upside)
Volume
4.23 million shares
Average Volume
14.94 million shares
Today's Range
$85.24
$86.46
50-Day Range
$77.70
$90.13
52-Week Range
$73.31
$111.58
Dividend Yield
3.70%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$524.28 -0.52 (-0.10%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $524.95, reflecting a strong market position and investor confidence in the company's growth potential.
  • Thermo Fisher Scientific Inc. reported a quarterly earnings per share (EPS) of $5.36, exceeding analysts' expectations, which indicates robust financial performance and effective management.
  • The company has shown a revenue increase of 2.9% compared to the same quarter last year, suggesting consistent demand for its life sciences solutions and laboratory products.

Cons of Thermo Fisher Scientific

  • The company has a relatively high P/E ratio of 30.36, which may suggest that the stock is overvalued compared to its earnings, potentially leading to lower returns for investors.
  • Recent insider selling, with a 7.99% decrease in their position, could indicate a lack of confidence from those closest to the company.
  • The stock has experienced fluctuations, with a 12-month high of $610.97 and a low of $385.46, indicating volatility that may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$197.90 billion
P/E Ratio
30.31
Consensus Rating
Moderate Buy
Consensus Price Target
$593.43 (+13.2% Upside)
Volume
1.11 million shares
Average Volume
2.42 million shares
Today's Range
$523.89
$530.83
50-Day Range
$449.68
$544.44
52-Week Range
$385.46
$610.97
Dividend Yield
0.33%
Amgen stock logo

11. Amgen NASDAQ:AMGN

$293.99 +3.86 (+1.33%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $315, reflecting a stable valuation in the market.
  • Amgen Inc. reported earnings per share (EPS) of $6.02 for the latest quarter, significantly exceeding analysts' expectations, indicating strong financial performance.
  • The company has a solid revenue growth of 9.4% year-over-year, showcasing its ability to expand and generate more income.

Cons of Amgen

  • The payout ratio is currently at 77.84%, which indicates that a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth.
  • Despite recent upgrades, the stock has a mixed analyst outlook with a notable number of "Hold" ratings, suggesting uncertainty about future performance.
  • Amgen Inc. operates in a highly competitive pharmaceutical market, which can impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$158.47 billion
P/E Ratio
24.07
Consensus Rating
Hold
Consensus Price Target
$309.42 (+5.2% Upside)
Volume
810,734 shares
Average Volume
2.77 million shares
Today's Range
$289.44
$296.13
50-Day Range
$271.18
$301.94
52-Week Range
$253.30
$335.88
Dividend Yield
3.28%
Intuitive Surgical stock logo

12. Intuitive Surgical NASDAQ:ISRG

$435.08 +5.49 (+1.28%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Recent analyst ratings indicate strong confidence in the stock, with fourteen analysts giving it a Buy rating, suggesting a positive outlook for future performance.
  • The current stock price is around $448, which may present a buying opportunity for investors looking to enter at a lower price point compared to its one-year high of $616.
  • Intuitive Surgical, Inc. has a robust market capitalization of approximately $160.63 billion, indicating a strong position in the healthcare sector and potential for growth.

Cons of Intuitive Surgical

  • Evercore ISI recently cut their price target from $535 to $450, indicating a more cautious outlook and potential challenges ahead for the stock.
  • Insider selling has been notable, with significant shares sold by executives, which could signal a lack of confidence in the company's short-term performance.
  • The stock has experienced volatility, with a beta of 1.61, suggesting that it may be more susceptible to market fluctuations compared to other stocks.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$156.00 billion
P/E Ratio
60.70
Consensus Rating
Moderate Buy
Consensus Price Target
$584.76 (+34.4% Upside)
Volume
1.10 million shares
Average Volume
2.06 million shares
Today's Range
$430.00
$438.10
50-Day Range
$429.59
$483.36
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Danaher stock logo

13. Danaher NYSE:DHR

$205.39 +2.93 (+1.45%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. recently reported strong earnings, with earnings per share of $1.80, exceeding analysts' expectations, indicating robust financial health and effective management.
  • The company has shown a year-over-year revenue growth of 3.4%, suggesting a positive trend in its business operations and market demand for its products.
  • Danaher Co. has set a favorable guidance for FY 2025, projecting earnings per share between 7.700 and 7.800, which could signal continued growth and profitability.

Cons of Danaher

  • Despite recent earnings growth, the company operates in a competitive market, which could pressure margins and limit future growth opportunities.
  • The stock's performance may be influenced by broader market conditions, which can lead to volatility and uncertainty for investors.
  • Danaher Co.'s dividend yield of 0.6% is relatively low compared to other investment opportunities, which may not attract income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.14 billion
P/E Ratio
43.72
Consensus Rating
Moderate Buy
Consensus Price Target
$244.60 (+19.1% Upside)
Volume
1.51 million shares
Average Volume
4.22 million shares
Today's Range
$202.85
$206.75
50-Day Range
$181.56
$215.05
52-Week Range
$171.00
$279.41
Dividend Yield
0.63%
Gilead Sciences stock logo

14. Gilead Sciences NASDAQ:GILD

$118.60 +1.42 (+1.21%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Gilead Sciences, Inc. has received multiple upgrades from analysts, including a recent increase in price targets, indicating strong market confidence in the company's future performance.
  • The current stock price is around $117.92, which reflects a solid position in the market and potential for growth based on recent analyst ratings.
  • With a consensus rating of "Moderate Buy" from analysts, the stock is viewed positively, suggesting that many believe it is a good investment opportunity.

Cons of Gilead Sciences

  • Despite positive ratings, the stock has experienced fluctuations, which may indicate volatility and risk for potential investors.
  • Insider selling activity, while not uncommon, can raise concerns about the executives' confidence in the company's future performance.
  • The company has a relatively high debt-to-equity ratio, which suggests that it relies significantly on borrowed funds to finance its operations, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.93 billion
P/E Ratio
23.59
Consensus Rating
Moderate Buy
Consensus Price Target
$118.08 (-0.4% Downside)
Volume
3.06 million shares
Average Volume
8.06 million shares
Today's Range
$115.80
$118.60
50-Day Range
$110.28
$120.47
52-Week Range
$84.34
$121.83
Dividend Yield
2.71%
Pfizer stock logo

15. Pfizer NYSE:PFE

$24.74 -0.05 (-0.18%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $28.41, which is within a reasonable range compared to its 12-month high of $30.43, indicating potential for growth.
  • Pfizer Inc. reported a significant increase in quarterly revenue, showing a year-over-year growth of over 10%, which reflects strong demand for its biopharmaceutical products.
  • The company has consistently exceeded earnings expectations, with recent earnings per share (EPS) reported at $0.78, surpassing analyst estimates, which can indicate strong operational performance.

Cons of Pfizer

  • Despite recent growth, the stock has faced competition from other biopharmaceutical companies, which could impact market share and profitability.
  • Analysts have issued a mix of ratings, with a notable number of "Hold" ratings, indicating uncertainty about the stock's future performance.
  • The company's net margin of 16.84% may not be as high as some competitors, which could raise concerns about its efficiency and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.58 billion
P/E Ratio
13.15
Consensus Rating
Hold
Consensus Price Target
$28.35 (+14.6% Upside)
Volume
34.91 million shares
Average Volume
46.87 million shares
Today's Range
$24.61
$24.95
50-Day Range
$23.56
$27.37
52-Week Range
$20.92
$29.82
Dividend Yield
6.94%
Boston Scientific stock logo

16. Boston Scientific NYSE:BSX

$94.88 -0.53 (-0.56%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Recent analyst upgrades have increased the target price for Boston Scientific Co. to as high as $135.00, indicating strong market confidence in the company's growth potential.
  • The current stock price is around $96.73, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $109.50.
  • Boston Scientific Co. has a solid market capitalization of approximately $143.33 billion, reflecting its strong position in the medical device industry.

Cons of Boston Scientific

  • Insider selling has been significant, with over 174,000 shares sold recently, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The stock has experienced a decrease in ownership percentages among insiders, which could signal a lack of confidence in the company's future prospects.
  • Despite positive analyst ratings, the stock has shown volatility, with a recent decline of about 0.9%, indicating potential instability in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.45 billion
P/E Ratio
56.42
Consensus Rating
Buy
Consensus Price Target
$120.71 (+27.2% Upside)
Volume
4.32 million shares
Average Volume
7.95 million shares
Today's Range
$94.56
$95.80
50-Day Range
$95.41
$108.15
52-Week Range
$80.64
$109.50
Dividend Yield
N/A
Stryker stock logo

17. Stryker NYSE:SYK

$364.08 -0.52 (-0.14%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $375, which reflects a stable position in the market.
  • Fifteen investment analysts have rated Stryker Co. with a Buy rating, indicating strong confidence in the company's future performance.
  • Wells Fargo recently raised their price target for Stryker Co. from $435 to $445, suggesting positive growth expectations.

Cons of Stryker

  • Recent insider selling, including a director selling 200,000 shares, may raise concerns about the company's future outlook.
  • The stock has experienced fluctuations, with a one-year low of $329.16 and a high of $406.19, indicating potential volatility.
  • Analysts have issued mixed ratings, with some lowering their ratings, which could reflect uncertainty in the company's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.12 billion
P/E Ratio
48.20
Consensus Rating
Moderate Buy
Consensus Price Target
$432.14 (+18.7% Upside)
Volume
621,552 shares
Average Volume
1.41 million shares
Today's Range
$363.37
$370.60
50-Day Range
$364.07
$394.67
52-Week Range
$329.16
$406.19
Dividend Yield
0.91%
Medtronic stock logo

18. Medtronic NYSE:MDT

$95.31 -0.14 (-0.15%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $97.88, which is near its 12-month high of $99.37, indicating strong market performance.
  • Medtronic plc reported a quarterly earnings per share of $1.26, surpassing analysts' expectations, which reflects robust financial health and operational efficiency.
  • The company has shown a year-over-year revenue increase of 7.7%, suggesting growth potential and a solid market position in the medical technology sector.

Cons of Medtronic

  • The payout ratio is currently at 78.24%, which may indicate that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
  • Some analysts have issued a "Sell" rating, reflecting concerns about the stock's valuation and future performance amidst market volatility.
  • The stock has a relatively high P/E ratio of 26.96, which may suggest that it is overvalued compared to its earnings, posing a risk for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$122.34 billion
P/E Ratio
26.27
Consensus Rating
Moderate Buy
Consensus Price Target
$102.41 (+7.5% Upside)
Volume
2.41 million shares
Average Volume
7.59 million shares
Today's Range
$95.06
$96.41
50-Day Range
$89.35
$98.46
52-Week Range
$79.29
$99.37
Dividend Yield
2.98%
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$48.58 +0.50 (+1.03%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple upgrades from analysts, including a recent upgrade to an "overweight" rating, indicating strong confidence in the company's future performance.
  • The current stock price is around $50, which is below the consensus price target of approximately $62.67, suggesting potential for price appreciation.
  • Sanofi reported a significant revenue of $11.34 billion in its latest quarterly earnings, exceeding analysts' expectations, which reflects strong operational performance.

Cons of Sanofi

  • Sanofi's earnings per share for the latest quarter missed analysts' consensus estimates, which may raise concerns about its short-term profitability.
  • The company's revenue decreased by 7.0% compared to the same quarter last year, indicating potential challenges in maintaining growth.
  • Despite positive analyst ratings, the stock has shown volatility, which could deter risk-averse investors looking for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.34 billion
P/E Ratio
11.68
Consensus Rating
Buy
Consensus Price Target
$62.67 (+29.0% Upside)
Volume
877,919 shares
Average Volume
2.74 million shares
Today's Range
$48.26
$48.71
50-Day Range
$45.07
$51.35
52-Week Range
$44.62
$60.12
Dividend Yield
3.32%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$407.98 +0.19 (+0.05%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company recently reported earnings per share (EPS) of $4.52, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • Vertex Pharmaceuticals Incorporated achieved a revenue of $2.94 billion for the quarter, surpassing estimates, showcasing its robust market position and demand for its products.
  • The stock price is currently around $389.68, reflecting a significant investment by insiders, which can be a positive signal about the company's future prospects.

Cons of Vertex Pharmaceuticals

  • Despite recent successes, the company has a history of fluctuating earnings, including a loss of ($12.83) EPS during the same quarter last year, which may raise concerns about consistency.
  • Insider ownership is relatively low at 0.20%, which could indicate less alignment between management and shareholder interests.
  • Some analysts have downgraded the stock from "strong-buy" to "buy," suggesting a potential decrease in investor confidence and future performance expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$104.65 billion
P/E Ratio
29.18
Consensus Rating
Moderate Buy
Consensus Price Target
$494.38 (+21.2% Upside)
Volume
443,542 shares
Average Volume
1.64 million shares
Today's Range
$402.58
$409.47
50-Day Range
$366.54
$472.27
52-Week Range
$362.50
$519.88
Dividend Yield
N/A
CVS Health stock logo

21. CVS Health NYSE:CVS

$78.40 +0.50 (+0.64%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a solid revenue growth of over 8% compared to the same quarter last year, reflecting its ability to expand its market presence.
  • CVS Health Co. has a current stock price around $76.78, which is near its 1-year high, suggesting positive market sentiment and potential for further appreciation.

Cons of CVS Health

  • The company's net margin is relatively low at 1.17%, which may indicate challenges in maintaining profitability amidst rising operational costs.
  • CVS Health Co. has a debt-to-equity ratio of 0.74, suggesting a moderate level of debt that could pose risks if interest rates rise or if the company faces financial difficulties.
  • Insider selling activity has been noted, with a director recently selling a significant number of shares, which could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$99.49 billion
P/E Ratio
21.91
Consensus Rating
Moderate Buy
Consensus Price Target
$79.80 (+1.8% Upside)
Volume
4.38 million shares
Average Volume
9.32 million shares
Today's Range
$77.37
$79.68
50-Day Range
$61.45
$77.89
52-Week Range
$43.56
$79.68
Dividend Yield
3.41%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$410.60 -4.54 (-1.09%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $425, reflecting a strong market position and investor interest.
  • HCA Healthcare, Inc. reported earnings per share of $6.84, exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 6.4%, suggesting growth potential in its operations.

Cons of HCA Healthcare

  • The stock has experienced fluctuations, with a 52-week high of $435.03 and a low of $289.98, indicating volatility that could concern risk-averse investors.
  • Recent downgrades from analysts, including a shift from "outperform" to "peer perform," may signal caution regarding future performance.
  • The company has a negative return on equity, which can be a red flag for investors looking for strong profitability metrics.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$96.14 billion
P/E Ratio
17.27
Consensus Rating
Moderate Buy
Consensus Price Target
$422.31 (+2.9% Upside)
Volume
641,782 shares
Average Volume
1.50 million shares
Today's Range
$410.51
$416.50
50-Day Range
$363.11
$437.46
52-Week Range
$289.98
$439.01
Dividend Yield
0.69%
McKesson stock logo

23. McKesson NYSE:MCK

$768.92 +5.37 (+0.70%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $853, reflecting a strong upward trend in recent analyst ratings and target price upgrades.
  • McKesson Co. has a low payout ratio of 13.08%, indicating that the company retains a significant portion of its earnings for reinvestment, which can lead to growth and increased shareholder value.
  • Recent upgrades from multiple analysts, including TD Cowen and Deutsche Bank, suggest strong confidence in the company's future performance, with target prices reaching as high as $864.

Cons of McKesson

  • Insider selling has been significant, with executives selling over 43,000 shares recently, which may indicate a lack of confidence in the company's short-term prospects.
  • Despite the positive analyst ratings, the stock has experienced fluctuations, and the overall market conditions can impact its performance negatively.
  • Only 0.08% of the stock is currently owned by company insiders, which may suggest a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.64 billion
P/E Ratio
30.66
Consensus Rating
Moderate Buy
Consensus Price Target
$829.08 (+7.8% Upside)
Volume
258,818 shares
Average Volume
864,052 shares
Today's Range
$752.47
$775.70
50-Day Range
$658.78
$772.61
52-Week Range
$492.39
$776.14
Dividend Yield
0.43%
GSK stock logo

24. GSK NYSE:GSK

$43.60 +0.06 (+0.13%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $40.63, which reflects a stable market position and potential for growth.
  • GSK plc reported earnings per share (EPS) of $1.23, exceeding consensus estimates, indicating strong financial performance.
  • The company has a robust market capitalization of approximately $82.74 billion, suggesting a solid foundation for future investments.

Cons of GSK

  • The company has a debt-to-equity ratio of 1.07, which may raise concerns about financial leverage and risk management.
  • GSK plc's quick ratio of 0.57 suggests potential liquidity issues, indicating that the company may struggle to meet short-term obligations.
  • Despite recent positive earnings, the stock has experienced fluctuations, which could indicate volatility and uncertainty in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.69 billion
P/E Ratio
20.18
Consensus Rating
Reduce
Consensus Price Target
$37.38 (-14.3% Downside)
Volume
2.36 million shares
Average Volume
5.14 million shares
Today's Range
$43.21
$43.75
50-Day Range
$36.79
$45.52
52-Week Range
$31.72
$45.59
Dividend Yield
3.89%
Bristol Myers Squibb stock logo

25. Bristol Myers Squibb NYSE:BMY

$43.56 -0.40 (-0.90%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company recently reported strong quarterly earnings, with an EPS of $1.46, significantly exceeding expectations, indicating robust financial health.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future growth.
  • The current stock price is around $XX, reflecting a stable investment opportunity in the biopharmaceutical sector.

Cons of Bristol Myers Squibb

  • The company has a high dividend payout ratio of 100%, which may raise concerns about sustainability if earnings do not grow as expected.
  • Recent revenue growth was only modest, with a year-over-year increase of just 0.6%, indicating potential challenges in expanding market share.
  • Competition in the biopharmaceutical industry is intense, with many companies developing similar therapies, which could impact Bristol-Myers Squibb's market position.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.65 billion
P/E Ratio
17.56
Consensus Rating
Hold
Consensus Price Target
$57.14 (+31.2% Upside)
Volume
8.80 million shares
Average Volume
13.53 million shares
Today's Range
$43.29
$44.23
50-Day Range
$43.45
$48.45
52-Week Range
$42.96
$63.33
Dividend Yield
5.64%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$296.42 -4.31 (-1.43%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group's quarterly revenue has increased by 11.0% compared to the same quarter last year, indicating strong growth potential.
  • The current stock price is around $306.57, which is positioned well within its 12-month range, suggesting stability and potential for appreciation.
  • The company has set its FY 2025 guidance at 29.600 EPS, showing confidence in future earnings performance.

Cons of Cigna Group

  • Insider selling activity has been noted, with a significant sale by an insider, which may raise concerns about the company's future prospects.
  • The stock has experienced fluctuations, with a 12-month high of $358.88 and a low of $256.89, indicating volatility that could deter risk-averse investors.
  • Some analysts have downgraded their ratings, reflecting mixed sentiments in the market regarding the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.13 billion
P/E Ratio
16.18
Consensus Rating
Moderate Buy
Consensus Price Target
$372.69 (+25.7% Upside)
Volume
433,044 shares
Average Volume
1.78 million shares
Today's Range
$295.88
$301.35
50-Day Range
$267.26
$311.24
52-Week Range
$256.89
$358.88
Dividend Yield
1.97%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$351.40 -1.85 (-0.52%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$79.11 billion
P/E Ratio
14.95
Consensus Rating
Moderate Buy
Consensus Price Target
$412.00 (+17.2% Upside)
Volume
590,530 shares
Average Volume
1.97 million shares
Today's Range
$350.48
$355.29
50-Day Range
$274.84
$362.47
52-Week Range
$273.71
$510.24
Dividend Yield
1.91%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$141.86 +0.75 (+0.53%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $143.73, which may present a buying opportunity for investors looking for value in the animal health sector.
  • Zoetis Inc. reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $1.76, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $64.91 billion, reflecting its strong position in the animal health market.

Cons of Zoetis

  • Recent downgrades from several analysts, including a cut from "strong-buy" to "hold," may signal concerns about the stock's short-term performance.
  • The stock has experienced fluctuations, with a 52-week high of $196.55 and a low of $139.34, indicating volatility that could deter risk-averse investors.
  • Analysts have mixed ratings, with five giving a "buy" and five a "hold," suggesting uncertainty in the stock's future trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$62.88 billion
P/E Ratio
24.42
Consensus Rating
Hold
Consensus Price Target
$196.71 (+38.7% Upside)
Volume
1.28 million shares
Average Volume
3.04 million shares
Today's Range
$140.65
$143.36
50-Day Range
$141.03
$156.69
52-Week Range
$139.34
$196.55
Dividend Yield
1.39%
Alnylam Pharmaceuticals stock logo

29. Alnylam Pharmaceuticals NASDAQ:ALNY

$472.36 +11.90 (+2.58%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Recent upgrades from multiple analysts, including a boost in price targets, indicate strong market confidence in Alnylam Pharmaceuticals, Inc.'s growth potential.
  • The current stock price is around $456, reflecting a significant increase from its one-year low, suggesting positive momentum in the market.
  • Twenty-four research analysts have rated the stock with a Buy rating, showcasing widespread optimism about the company's future performance.

Cons of Alnylam Pharmaceuticals

  • The company has a high debt-to-equity ratio of 4.10, which may raise concerns about its financial leverage and long-term sustainability.
  • Despite positive analyst ratings, the stock has a negative price-to-earnings ratio, indicating that the company is not currently profitable, which could deter risk-averse investors.
  • Insider selling activity has been significant, with over 75,000 shares sold recently, which might signal a lack of confidence among executives regarding the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$61.95 billion
P/E Ratio
-191.35
Consensus Rating
Moderate Buy
Consensus Price Target
$457.08 (-3.2% Downside)
Volume
1.13 million shares
Average Volume
981,785 shares
Today's Range
$453.83
$473.65
50-Day Range
$418.91
$482.13
52-Week Range
$205.87
$484.21
Dividend Yield
N/A
Cencora stock logo

30. Cencora NYSE:COR

$317.50 -0.50 (-0.16%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is approximately $290, which may present a buying opportunity for investors looking for growth in the pharmaceutical distribution sector.
  • Insider ownership stands at 10.80%, indicating that executives have a significant stake in the company, which can align their interests with those of shareholders.
  • Recent insider transactions show that executives are actively managing their holdings, which can signal confidence in the company's future performance.

Cons of Cencora

  • Recent insider sales, totaling over 55,000 shares, may raise concerns about the executives' confidence in the company's short-term performance.
  • The decrease in insider ownership percentages, such as the 11.49% drop for the CEO, could indicate potential issues or a lack of confidence in future growth.
  • High institutional ownership, while generally a positive sign, can also lead to volatility if large investors decide to sell their positions quickly.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$61.56 billion
P/E Ratio
32.67
Consensus Rating
Moderate Buy
Consensus Price Target
$320.00 (+0.8% Upside)
Volume
661,736 shares
Average Volume
1.56 million shares
Today's Range
$313.58
$319.87
50-Day Range
$278.18
$318.01
52-Week Range
$221.95
$319.87
Dividend Yield
0.69%
Regeneron Pharmaceuticals stock logo

31. Regeneron Pharmaceuticals NASDAQ:REGN

$561.63 -3.00 (-0.53%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health.
  • Regeneron Pharmaceuticals, Inc. has shown a year-over-year revenue increase, suggesting consistent growth and demand for its products.
  • The current stock price is around $600, which may present a buying opportunity for investors looking for value in the biotech sector.

Cons of Regeneron Pharmaceuticals

  • Despite recent growth, the stock has experienced volatility, with a significant 52-week high and low range, which may indicate risk for investors.
  • Some analysts have downgraded their ratings, suggesting caution and potential challenges ahead for the company's stock performance.
  • The biotech sector can be highly competitive and subject to regulatory changes, which may impact the company's future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$59.65 billion
P/E Ratio
14.18
Consensus Rating
Moderate Buy
Consensus Price Target
$817.88 (+45.6% Upside)
Volume
971,961 shares
Average Volume
1.11 million shares
Today's Range
$541.00
$563.77
50-Day Range
$545.94
$600.00
52-Week Range
$476.49
$1,024.36
Dividend Yield
0.62%
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$186.76 +0.20 (+0.11%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The stock has received multiple recent upgrades from analysts, indicating positive sentiment and potential for growth.
  • Current price targets from various analysts suggest a favorable outlook, with an average target price around $205.40, which is above the current stock price.
  • Becton, Dickinson and Company has a strong reputation in the healthcare sector, developing essential medical supplies and devices that are in high demand.

Cons of Becton, Dickinson and Company

  • Despite positive ratings, nine analysts have issued a Hold rating, indicating caution and uncertainty about the stock's short-term performance.
  • Recent price targets have varied, with some analysts setting targets below the average, which may suggest differing opinions on the company's valuation.
  • The healthcare sector can be highly competitive and subject to regulatory changes, which may impact Becton, Dickinson and Company's operations and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.51 billion
P/E Ratio
33.58
Consensus Rating
Hold
Consensus Price Target
$205.40 (+10.0% Upside)
Volume
505,780 shares
Average Volume
2.44 million shares
Today's Range
$186.00
$189.25
50-Day Range
$172.50
$199.50
52-Week Range
$163.33
$251.99
Dividend Yield
2.23%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$629.90 +13.76 (+2.23%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $620, reflecting a strong market position and investor interest.
  • IDEXX Laboratories, Inc. reported earnings per share (EPS) of $3.63 for the latest quarter, exceeding expectations, which indicates robust financial performance.
  • The company has shown a revenue increase of 10.6% compared to the same quarter last year, suggesting growth potential in its market segments.

Cons of IDEXX Laboratories

  • Insider selling has been notable, with executives selling over 54,000 shares recently, which may signal a lack of confidence in the stock's short-term performance.
  • The stock has a high price-to-earnings (P/E) ratio of 51.63, which could indicate that it is overvalued compared to its earnings, making it a riskier investment.
  • Despite strong revenue growth, the company operates in a competitive market, which could impact future growth and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.46 billion
P/E Ratio
52.52
Consensus Rating
Moderate Buy
Consensus Price Target
$656.50 (+4.2% Upside)
Volume
156,931 shares
Average Volume
664,711 shares
Today's Range
$621.83
$633.81
50-Day Range
$616.15
$682.78
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
argenex stock logo

34. argenex NASDAQ:ARGX

$804.18 +7.26 (+0.91%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company recently reported earnings per share (EPS) of $3.74, significantly exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • Argenx SE achieved revenue of approximately $866.79 million for the quarter, surpassing consensus estimates, showcasing robust demand for its products.
  • With a net margin of around 40.98%, argenx SE demonstrates effective cost management and profitability, which can be attractive to investors looking for financially healthy companies.

Cons of argenex

  • Despite recent successes, the biotechnology sector can be highly volatile, and any setbacks in product development or regulatory approvals could negatively impact stock performance.
  • Argenx SE's reliance on a limited number of products for revenue could pose risks if market conditions change or if competition increases.
  • The company has experienced fluctuations in stock price, which may indicate uncertainty among investors regarding its long-term growth trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.20 billion
P/E Ratio
41.23
Consensus Rating
Buy
Consensus Price Target
$817.53 (+1.7% Upside)
Volume
123,270 shares
Average Volume
371,206 shares
Today's Range
$794.90
$810.16
50-Day Range
$637.56
$804.90
52-Week Range
$510.05
$810.16
Dividend Yield
N/A
Veeva Systems stock logo

35. Veeva Systems NYSE:VEEV

$286.04 -0.55 (-0.19%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $296, reflecting a strong market position and investor interest in the company's growth potential.
  • Veeva Systems Inc. has received multiple upgrades from analysts, with target prices reaching as high as $355, indicating confidence in future performance.
  • Insider activity shows significant transactions, with insiders selling shares at high prices, suggesting they believe the stock is at a favorable valuation.

Cons of Veeva Systems

  • Recent insider sales, including significant transactions by senior executives, may raise concerns about the company's future performance and insider confidence.
  • The stock has experienced fluctuations, with a recent decline of about 1.4%, which could indicate volatility and uncertainty in the market.
  • Analysts have mixed ratings, with some downgrading the stock from "buy" to "hold," suggesting caution among market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.88 billion
P/E Ratio
58.73
Consensus Rating
Moderate Buy
Consensus Price Target
$307.58 (+7.5% Upside)
Volume
376,368 shares
Average Volume
1.32 million shares
Today's Range
$285.78
$289.00
50-Day Range
$268.85
$306.45
52-Week Range
$201.54
$310.50
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

36. Takeda Pharmaceutical NYSE:TAK

$13.74 +0.03 (+0.18%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price recently reached a new 52-week high, indicating strong market performance and investor confidence.
  • Takeda Pharmaceutical Company Limited reported earnings per share (EPS) of $0.52, surpassing analyst expectations, which reflects effective management and operational efficiency.
  • The company has a solid market capitalization of approximately $48 billion, suggesting a stable financial foundation and potential for growth.

Cons of Takeda Pharmaceutical

  • Zacks Research recently downgraded the stock from a "hold" rating to a "strong sell" rating, indicating concerns about the company's future performance.
  • The company reported revenue of $7.45 billion, which fell short of analyst expectations, suggesting potential challenges in meeting market demands.
  • Takeda Pharmaceutical Company Limited has a relatively high P/E ratio, which may indicate that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.70 billion
P/E Ratio
45.78
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
1.89 million shares
Average Volume
2.60 million shares
Today's Range
$13.71
$13.79
50-Day Range
$13.73
$15.50
52-Week Range
$12.80
$15.69
Dividend Yield
3.92%
Edwards Lifesciences stock logo

37. Edwards Lifesciences NYSE:EW

$72.83 -1.11 (-1.50%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Market Capitalization
$42.70 billion
P/E Ratio
10.47
Consensus Rating
Moderate Buy
Consensus Price Target
$87.06 (+19.5% Upside)
Volume
1.98 million shares
Average Volume
4.47 million shares
Today's Range
$72.30
$73.69
50-Day Range
$73.80
$81.76
52-Week Range
$64.89
$83.00
Dividend Yield
N/A
Haleon stock logo

38. Haleon NYSE:HLN

$9.06 +0.06 (+0.61%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $8.94, which may present a buying opportunity for investors looking for growth potential.
  • Haleon plc has recently increased its semi-annual dividend to $0.0555 per share, reflecting a commitment to returning value to shareholders.
  • The company has a market capitalization of approximately $39.81 billion, indicating a strong presence in the consumer healthcare market.

Cons of Haleon

  • The stock has a relatively high price-to-earnings (P/E) ratio of around 22.91, which may indicate that it is overvalued compared to its earnings.
  • Haleon plc has a current ratio of 0.87, suggesting potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
  • The company has a beta of 0.20, indicating lower volatility compared to the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.32 billion
P/E Ratio
23.22
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+36.1% Upside)
Volume
8.10 million shares
Average Volume
12.19 million shares
Today's Range
$9.02
$9.10
50-Day Range
$8.74
$9.91
52-Week Range
$8.71
$11.42
Dividend Yield
1.26%
ResMed stock logo

39. ResMed NYSE:RMD

$273.12 +1.12 (+0.41%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The company reported earnings per share of $2.55 for the latest quarter, exceeding expectations, which indicates strong financial performance and potential for growth.
  • ResMed Inc. has shown a year-over-year revenue increase of over 10%, suggesting a robust demand for its medical devices and cloud-based software applications.
  • The current stock price is around $282, reflecting a positive market sentiment and potential for appreciation as analysts have a consensus price target of approximately $294.20.

Cons of ResMed

  • Insider selling has been observed, with executives selling shares valued at over $5 million recently, which may raise concerns about their confidence in the company's future performance.
  • The dividend yield is relatively low at 0.9%, which might not attract income-focused investors looking for higher returns from dividends.
  • Despite positive growth, the stock has seen fluctuations, and the market can be unpredictable, which may pose risks for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.88 billion
P/E Ratio
28.73
Consensus Rating
Moderate Buy
Consensus Price Target
$292.91 (+7.2% Upside)
Volume
414,773 shares
Average Volume
984,158 shares
Today's Range
$271.13
$277.33
50-Day Range
$267.62
$293.48
52-Week Range
$199.92
$293.81
Dividend Yield
0.88%
Agilent Technologies stock logo

40. Agilent Technologies NYSE:A

$139.05 +2.43 (+1.78%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $122, which reflects a strong performance in the market, indicating investor confidence.
  • Agilent Technologies, Inc. reported a revenue increase of over 10% compared to the same quarter last year, showcasing robust growth in its business operations.
  • The company has a solid return on equity of 25.51%, which suggests effective management and profitability relative to shareholder equity.

Cons of Agilent Technologies

  • The price-to-earnings (P/E) ratio is around 32.63, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • The PEG ratio of 4.62 suggests that the stock may be expensive relative to its growth rate, which could deter value-focused investors.
  • Despite a strong revenue report, the company faces competition in the life sciences and diagnostics markets, which could impact future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.41 billion
P/E Ratio
32.63
Consensus Rating
Moderate Buy
Consensus Price Target
$148.69 (+6.9% Upside)
Volume
694,926 shares
Average Volume
1.93 million shares
Today's Range
$136.76
$139.84
50-Day Range
$113.32
$141.91
52-Week Range
$96.43
$153.84
Dividend Yield
0.71%
Cardinal Health stock logo

41. Cardinal Health NYSE:CAH

$154.32 -2.56 (-1.63%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $120, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Cardinal Health, Inc. recently reported earnings that exceeded analysts' expectations, indicating strong operational performance and potential for future growth.
  • The company has a solid market capitalization of approximately $37.66 billion, suggesting stability and a significant presence in the healthcare industry.

Cons of Cardinal Health

  • The company has a negative return on equity of 74.45%, which may indicate inefficiencies in generating profit from shareholders' equity.
  • Cardinal Health, Inc. has a net margin of only 0.70%, suggesting that the company retains a small portion of revenue as profit, which could limit growth potential.
  • Recent insider selling of 271,676 shares may raise concerns about the confidence of company executives in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.66 billion
P/E Ratio
23.92
Consensus Rating
Moderate Buy
Consensus Price Target
$166.00 (+7.6% Upside)
Volume
962,952 shares
Average Volume
2.41 million shares
Today's Range
$154.54
$157.35
50-Day Range
$146.18
$158.64
52-Week Range
$106.98
$168.44
Dividend Yield
1.30%
BeOne Medicines stock logo

42. BeOne Medicines NASDAQ:ONC

$330.44 +10.34 (+3.23%)
As of 03:15 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$36.22 billion
P/E Ratio
-191.00
Consensus Rating
Moderate Buy
Consensus Price Target
$340.30 (+3.0% Upside)
Volume
99,230 shares
Average Volume
406,350 shares
Today's Range
$322.54
$332.33
50-Day Range
$288.10
$351.13
52-Week Range
$170.99
$355.30
Dividend Yield
N/A
Alcon stock logo

43. Alcon NYSE:ALC

$72.76 +0.71 (+0.98%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth of over 20%, which suggests strong investor confidence.
  • The company has a significant average daily trading volume, which can indicate liquidity and investor interest.

Cons of Alcon

  • Despite recent growth, the short percentage of float remains low, which may indicate a lack of strong bullish sentiment among investors.
  • There has been a notable month-to-month change in short interest, which could suggest volatility in investor sentiment.
  • The days to cover ratio indicates that it may take a while for short sellers to cover their positions, which can lead to potential price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.89 billion
P/E Ratio
33.84
Consensus Rating
Moderate Buy
Consensus Price Target
$93.41 (+28.4% Upside)
Volume
1.53 million shares
Average Volume
1.75 million shares
Today's Range
$72.47
$73.13
50-Day Range
$71.99
$90.14
52-Week Range
$71.55
$99.20
Dividend Yield
N/A
Insmed stock logo

44. Insmed NASDAQ:INSM

$164.62 +2.29 (+1.41%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$34.75 billion
P/E Ratio
-28.79
Consensus Rating
Moderate Buy
Consensus Price Target
$149.06 (-9.4% Downside)
Volume
1.07 million shares
Average Volume
2.70 million shares
Today's Range
$162.08
$166.44
50-Day Range
$109.30
$164.40
52-Week Range
$60.40
$166.44
Dividend Yield
N/A
IQVIA stock logo

45. IQVIA NYSE:IQV

$204.23 +6.06 (+3.06%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $206.84, reflecting a strong market position and potential for growth.
  • IQVIA Holdings Inc. has received multiple upgrades from analysts, with target prices reaching as high as $235.00, indicating positive market sentiment.
  • The company reported a year-over-year revenue increase of 5.3%, showcasing its ability to grow despite market challenges.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio of 2.45, which may indicate financial risk and reliance on borrowed funds.
  • Insider ownership is low at 1.60%, which could suggest a lack of confidence from those closest to the company.
  • Despite recent growth, the stock has experienced fluctuations, with a 1-year high of $237.34 and a low of $134.65, indicating potential volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.73 billion
P/E Ratio
29.56
Consensus Rating
Moderate Buy
Consensus Price Target
$236.45 (+15.8% Upside)
Volume
812,316 shares
Average Volume
1.84 million shares
Today's Range
$198.64
$206.20
50-Day Range
$176.72
$206.84
52-Week Range
$134.65
$237.34
Dividend Yield
N/A
GE HealthCare Technologies stock logo

46. GE HealthCare Technologies NASDAQ:GEHC

$71.85 +0.84 (+1.18%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company reported a strong quarterly earnings performance, exceeding analysts' expectations with earnings per share significantly higher than the consensus estimate.
  • GE HealthCare Technologies Inc. has demonstrated a solid return on equity, indicating effective management and profitability relative to shareholder equity.
  • Recent revenue growth of approximately 3.5% year-over-year suggests a positive trend in sales, which can be a good indicator of the company's market position and demand for its products.

Cons of GE HealthCare Technologies

  • Despite recent earnings growth, the company faces competitive pressures in the healthcare technology sector, which could impact future profitability.
  • Some analysts have downgraded their ratings, indicating mixed sentiments about the stock's future performance, which could lead to volatility.
  • The dividend yield is relatively low at 0.2%, which may not attract income-focused investors looking for higher returns from dividends.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.83 billion
P/E Ratio
14.73
Consensus Rating
Moderate Buy
Consensus Price Target
$85.20 (+18.6% Upside)
Volume
1.44 million shares
Average Volume
3.89 million shares
Today's Range
$71.70
$72.83
50-Day Range
$69.96
$78.71
52-Week Range
$57.65
$94.80
Dividend Yield
0.20%
Humana stock logo

47. Humana NYSE:HUM

$270.96 -9.26 (-3.30%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The company has shown strong revenue growth, with a recent quarterly revenue increase of approximately 9.6% year-over-year, indicating robust demand for its insurance products.
  • Humana Inc. has a solid return on equity of 13.67%, which reflects effective management and profitability, making it an attractive option for investors seeking strong financial performance.
  • The current stock price is around $289.50, which is within a favorable range according to analysts' target prices, suggesting potential for appreciation.

Cons of Humana

  • The company recently missed earnings expectations, reporting $6.27 EPS compared to the consensus estimate of $6.32, which may raise concerns about its short-term profitability.
  • Humana Inc. has a relatively low net margin of 1.28%, which could indicate challenges in managing costs and profitability compared to competitors.
  • Some analysts have downgraded their price targets for Humana Inc., reflecting a cautious outlook on its stock performance in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.61 billion
P/E Ratio
20.81
Consensus Rating
Hold
Consensus Price Target
$298.83 (+10.3% Upside)
Volume
974,734 shares
Average Volume
1.78 million shares
Today's Range
$270.35
$281.00
50-Day Range
$246.89
$312.22
52-Week Range
$206.87
$315.35
Dividend Yield
1.22%
Mettler-Toledo International stock logo

48. Mettler-Toledo International NYSE:MTD

$1,290.73 +17.07 (+1.34%)
As of 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,274, reflecting a strong performance in the market.
  • The company reported earnings per share of $10.09, exceeding analysts' expectations, indicating robust financial health.
  • Revenue for the latest quarter was $983.22 million, surpassing estimates and showing a year-over-year growth of 3.9%.

Cons of Mettler-Toledo International

  • The company has a negative return on equity of 476.07%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • The P/E ratio stands at 33.06, which could indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite recent revenue growth, the company faces competitive pressures in the medical instruments sector, which could impact future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.60 billion
P/E Ratio
32.70
Consensus Rating
Hold
Consensus Price Target
$1,336.50 (+3.5% Upside)
Volume
51,307 shares
Average Volume
166,293 shares
Today's Range
$1,275.35
$1,300.00
50-Day Range
$1,191.70
$1,345.35
52-Week Range
$946.69
$1,486.76
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$27.48 +0.16 (+0.57%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $26.81, which may present a buying opportunity for investors looking for value in the technology sector.
  • Recent institutional investments indicate growing confidence in Koninklijke Philips, with significant increases in holdings by various hedge funds, suggesting potential for future growth.
  • Analyst ratings remain positive, with a consensus rating of "Buy," indicating that experts believe the stock has potential for appreciation.

Cons of Koninklijke Philips

  • Recent adjustments in institutional holdings, such as a 26.9% reduction by Wealth Enhancement Advisory Services LLC, may signal concerns about the company's short-term performance.
  • The stock has experienced volatility, with a 12-month low of $21.48, indicating potential risks for investors regarding price fluctuations.
  • Analysts have downgraded the stock from a "buy" to a "hold" rating, which may suggest that the stock is currently overvalued or that growth expectations have tempered.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.49 billion
P/E Ratio
144.77
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
229,462 shares
Average Volume
925,088 shares
Today's Range
$27.44
$27.63
50-Day Range
$26.21
$28.63
52-Week Range
$21.48
$32.62
Dividend Yield
3.01%
DexCom stock logo

50. DexCom NASDAQ:DXCM

$65.12 0.00 (0.00%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $80, which may present a buying opportunity for investors looking for growth in the medical device sector.
  • DexCom, Inc. specializes in continuous glucose monitoring systems, a growing market due to the increasing prevalence of diabetes, which could lead to higher demand for their products.
  • Recent insider trading activity indicates confidence in the company's future, as executives have been actively managing their stock positions.

Cons of DexCom

  • Recent insider sales, totaling 6,849 shares worth $564,733, may raise concerns about the executives' confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with recent trades showing a decrease in ownership percentages among executives, which could signal uncertainty.
  • As a company operating in the medical device industry, DexCom, Inc. faces regulatory challenges that could impact product approvals and market entry.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.53 billion
P/E Ratio
45.21
Consensus Rating
Moderate Buy
Consensus Price Target
$97.42 (+49.6% Upside)
Volume
1.63 million shares
Average Volume
4.20 million shares
Today's Range
$64.93
$66.37
50-Day Range
$65.12
$82.26
52-Week Range
$57.52
$93.25
Dividend Yield
N/A